Shares of Revance Therapeutics surged 18% Thursday after the company announced the Food and Drug Administration had approved Daxxify.
The company says Daxxify can diminish wrinkles for up to six months, twice as long as Botox.
The FDA’s decision comes years after Revance submitted Daxxify for approval, encountering delays due to the Covid-19 pandemic as well asMore than $14.6 billion. That’s how much the U.S. aesthetics procedures market was worth in 2021,Botox, which is derived from a toxin produced by the bacteria clostridium botulinum, was initially used to create a drug to treat two rare eye muscle disorders.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
FDA Approves New Botox RivalThe U.S. Food and Drug Administration approved a new antiwrinkle treatment that could be the most formidable challenger to date to market leader Botox
続きを読む »
More U.S. adults receiving mental health treatment since start of pandemicMore U.S. adults are receiving mental health treatment. Nearly 22% of all adults received some form of treatment in 2021 — up from about 19% just two years earlier. Go deeper:
続きを読む »
Chicago influencer shares tale of bad botox treatment; 'I look like Two-Face''I started thinking about it, and realized that people didn't know this was a side effect. I didn't know it was a side effect, and decided that I should share what happened to me,' Whitney Buha said.
続きを読む »
Analysis | In praise of iron fists: Trump leans into his authoritarian instinctsThe pattern has long been that Trump tests the waters — and then jumps in.
続きを読む »
Gavin Newsom encounters an unexpected antagonist: Joe BidenCalifornia Gov. Gavin Newsom finds himself at odds with Biden and other Democrats over pro-union legislation in his home state.
続きを読む »
Rents continue to skyrocket in NYC, Here is the average rent nowRents jumped up around 23% last year in New York City.
続きを読む »